NASDAQ:NAGE Niagen Bioscience (NAGE) Stock Price, News & Analysis $3.21 +0.06 (+1.90%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Niagen Bioscience Stock (NASDAQ:NAGE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Niagen Bioscience alerts:Sign Up Key Stats Today's Range$3.14▼$3.2450-Day Range$2.96▼$3.5352-Week Range$2.87▼$10.52Volume370,275 shsAverage Volume698,108 shsMarket Capitalization$255.64 millionP/E Ratio17.83Dividend YieldN/APrice Target$10.33Consensus RatingBuy Company Overview Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA. Read More Niagen Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreNAGE MarketRank™: Niagen Bioscience scored higher than 76% of companies evaluated by MarketBeat, and ranked 53rd out of 168 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingNiagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialNiagen Bioscience has a consensus price target of $10.33, representing about 221.9% upside from its current price of $3.21.Amount of Analyst CoverageNiagen Bioscience has only been the subject of 4 research reports in the past 90 days.Read more about Niagen Bioscience's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth7.69% Earnings GrowthEarnings for Niagen Bioscience are expected to grow by 7.69% in the coming year, from $0.13 to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Niagen Bioscience is 17.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.64.Price to Earnings Ratio vs. SectorThe P/E ratio of Niagen Bioscience is 17.83, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 13.58.Price to Book Value per Share RatioNiagen Bioscience has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.34% of the float of Niagen Bioscience has been sold short.Short Interest Ratio / Days to CoverNiagen Bioscience has a short interest ratio ("days to cover") of 7.24.Change versus previous monthShort interest in Niagen Bioscience has recently decreased by 5.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNiagen Bioscience does not currently pay a dividend.Dividend GrowthNiagen Bioscience does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.35 News SentimentNiagen Bioscience has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Niagen Bioscience this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for NAGE on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat Follows1 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Niagen Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders10.00% of the stock of Niagen Bioscience is held by insiders.Percentage Held by Institutions15.41% of the stock of Niagen Bioscience is held by institutions.Read more about Niagen Bioscience's insider trading history. Receive NAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAGE Stock News HeadlinesNiagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s ClubAugust 20 at 1:36 PM | finance.yahoo.comNiagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's ClubAugust 20 at 8:32 AM | businesswire.comA Dark Day Is Coming to AmericaKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift in the AI market is approaching, and time is short to prepare. Kaplan points to August 31st as a key turning point for AI investing. He argues the next phase will separate winners from losers, and reveals what he's watching instead of big names like Nvidia. | TradeSmith (Ad)NAGE Shines Spotlight on New NAD+ Skin‑Aging Trial as Cosmetic Demand Heats UpAugust 19 at 12:31 PM | tipranks.comNiagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor ConferenceAugust 12, 2026 | businesswire.comDoes Niagen Bioscience's (NAGE) Walmart NAD+ Push Redefine Its Healthy‑Aging Brand Narrative?August 8, 2026 | finance.yahoo.comNiagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair ValueAugust 6, 2026 | finance.yahoo.comNiagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace PresenceAugust 6, 2026 | businesswire.comSee More Headlines NAGE Stock Analysis - Frequently Asked Questions How have NAGE shares performed this year? Niagen Bioscience's stock was trading at $6.36 at the start of the year. Since then, NAGE stock has decreased by 49.5% and is now trading at $3.21. How were Niagen Bioscience's earnings last quarter? Niagen Bioscience, Inc. (NASDAQ:NAGE) announced its quarterly earnings data on Tuesday, August, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.01. The firm had revenue of $29.78 million for the quarter, compared to analysts' expectations of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a trailing twelve-month return on equity of 17.95%. Who are Niagen Bioscience's major shareholders? Top institutional shareholders of Niagen Bioscience include Tieton Capital Management LLC (2.52%), Bank of New York Mellon Corp (0.25%) and Stoneridge Investment Partners LLC (0.02%). Insiders that own company stock include Frank L Jaksch Jr, Brianna Gerber, Ozan Pamir and Kristin Patrick. View institutional ownership trends. How do I buy shares of Niagen Bioscience? Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2026Today8/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 NAGE's financial health is in the Red zone, according to TradeSmith. NAGE has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Personal Care Products Sub-IndustryPersonal Care Products Current SymbolNASDAQ:NAGE Previous SymbolNASDAQ:NAGE CIK1386570 Webchromadex.com Phone(310) 388-6706Fax949-419-0294Employees120Year FoundedN/APrice Target and Rating Average Price Target for Niagen Bioscience$10.33 High Price Target$11.00 Low Price Target$10.00 Potential Upside/Downside+221.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.18 Trailing P/E Ratio17.83 Forward P/E Ratio24.69 P/E GrowthN/ANet Income$17.38 million Net Margins12.39% Pretax Margin13.19% Return on Equity17.95% Return on Assets13.17% Debt Debt-to-Equity RatioN/A Current Ratio6.50 Quick Ratio5.13 Sales & Book Value Annual Sales$129.42 million Price / Sales1.98 Cash Flow$0.21 per share Price / Cash Flow15.53 Book Value$1.04 per share Price / Book3.09Miscellaneous Outstanding Shares79,640,000Free Float71,680,000Market Cap$255.64 million OptionableN/A Beta2.09 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:NAGE) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe world's #2 gold miner is running on fumes [it has to buy]Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...Golden Portfolio | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
